Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Johnson & Johnson : Janssen Leverages Wearable Technology to Reimagine Clinical Trial Design

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/18/2019 | 06:12am EST

TITUSVILLE - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the launch of the next evolution of digital clinical trial design with CHIEF-HF, the first-ever completely decentralized, mobile, indication-seeking clinical study.

To accelerate the study and fast-track results, all contact with participants will be done virtually, with no in-person clinical visits required. Drawing on previous experience, the Company is utilizing smart technology and wearable devices to more quickly and efficiently gather and analyze real-world evidence to assess the effectiveness of canagliflozin in adults with heart failure (HF), with or without type 2 diabetes (T2D). Through a collaboration with global research organization PRA Health Sciences and their innovative mobile clinical trial platform, CHIEF-HF (Canagliflozin: Impact on Health Status, Quality of Life and Functional Status in Heart Failure), will examine the use of canagliflozin compared to placebo on quality of life improvement scales, in participants with either preserved or reduced ejection fraction heart failure.

More about CHIEF-HF

CHIEF-HF will enroll participants 18 years or older who have clinically stable symptomatic HF with a baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) score of >40 and

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
12/11JOHNSON & JOHNSON : Janssen Pharmaceutical - DARZALEX Regimen Shows Significant ..
AQ
12/10JOHNSON & JOHNSON : appeals Oklahoma judge's opioid ruling
AQ
12/10JOHNSON & JOHNSON : to Host Investor Conference Call on Fourth-Quarter Results
PR
12/10JOHNSON & JOHNSON : Vaccine Regimen from Janssen and Bavarian Nordic to Support ..
AQ
12/10JOHNSON & JOHNSON : Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-..
AQ
12/10JOHNSON & JOHNSON : Janssen Pharmaceutical - DARZALEX Shows Overall Survival Ben..
AQ
12/10AMGEN : Phase 3 Study Combining Kyprolis, Darzalex Met Primary Endpoint
DJ
12/09WISETECH GLOBAL LTD (ASX : WTC) Acquires South Korean Solutions Provider, Ready ..
AQ
12/09JOHNSON & JOHNSON : Janssen to Acquire Investigational Bermekimab from XBiotech
PU
12/09XBiotech Shares Jump After Selling Bermekimab to Janssen
DJ
More news
Financials (USD)
Sales 2019 82 175 M
EBIT 2019 25 638 M
Net income 2019 17 334 M
Debt 2019 6 823 M
Yield 2019 2,66%
P/E ratio 2019 21,6x
P/E ratio 2020 19,1x
EV / Sales2019 4,61x
EV / Sales2020 4,33x
Capitalization 372 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 149,90  $
Last Close Price 141,38  $
Spread / Highest target 22,4%
Spread / Average Target 6,03%
Spread / Lowest Target -8,76%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.52%372 094
ROCHE HOLDING AG24.22%261 287
MERCK AND COMPANY16.73%227 076
PFIZER-12.19%212 123
NOVARTIS22.85%210 097
BRISTOL-MYERS SQUIBB COMPANY23.01%149 606